

INNOVATION VENTURES AVAILABLE TECHNOLOGIES

CONTACT US

Request Information

Permalink

Combination Therapy For CNS Lymphoma

Tech ID: 33640 / UC Case 2023-138-0

TECHNOLOGY DESCRIPTION

There are currently no effective therapies for CNS lymphoma. Although B-cell malignancies express CD19, few therapeutic modalities (including CAR-T cells and bispecific T-cell engager antibodies) have overcome severe CNS neurotoxicity. New research suggests that CD19 expression at BBB may mediate neurotoxicity. Our inventor has shown regression of highly refractory CNS lymphoma with tafasitamab and lenalidomide.

STAGE OF DEVELOPMENT

Phase 2 L-MIND trial in patients with refractory non-Hodgkin lymphoma.

RELATED MATERIALS

Tafasitamab at the blood-brain barrier - 01/23/2023

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney Gemma.Rooney@ucsf.edu tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

Refractory CNS Lymphoma,

B Cell Malignancy, CD19,

Tasasitamab, Lenalidomide

CATEGORIZED AS

Medical

Disease: Cancer

► Therapeutics

RELATED CASES

2023-138-0

ADDRESS

UCSF Innovation Ventures 600 16th St, Genentech Hall, S-272, San Francisco.CA 94158

CONTACT

Tel: innovation@ucsf.edu https://innovation.ucsf.edu Fax: CONNECT

© 2024, The Regents of the University of California Terms of use Privacy Notice